Lianhong Xu

USPTO Granted Patents = 47 (Patent Applications = 27)

CIPO Patents = 8 (Patent Applications = 6)

EPO Patents = 26 (Patent Applications = 32)

Average Co-Inventor Count = 4.9

ph-index = 8

Forward Citations = 284(Granted Patents)

Location History:

San Mateo, CA (US) (2008 - 2010)
Foster City, CA (US) (2012)
Palo Alto, CA (US) (2010 - 2024)
Durham, NC (US) (2023 - 2024)

Company Filing History:

31 out of 919

Gilead Sciences, Inc.

patents

6 out of 6

Brii Biosciences, Inc.

patents

4 out of 79

Gilead Pharmasset LLC

patents

4. 3 out of 623

Korea Research Institute of Chemical Technology

patents

5. 2 out of 4

Lilac Therapeutics, Inc.

Years Active: 2008-2025

Loading Chart...

47 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12390484 - Adenosine derivative and pharmaceutical composition comprising the same (2025-08-19),

2. 12370208 - Adenosine derivative and pharmaceutical composition comprising the same (2025-07-29),

3. 12370200 - Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof (2025-07-29),

4. 12257264 - Combination therapy for HIV with adenosine derivative and capsid inhibitors (2025-03-25),

5. 12240862 - Inhibitors of peptidylarginine deiminases (2025-03-04),

6. 12168002 - Heterocyclic carboxylate compounds as glycolate oxidase inhibitors (2024-12-17),

7. 11890297 - Combination therapy for HIV with adenosine derivative and capsid inhibitors (2024-02-06),

8. 11878965 - Inhibitors of peptidylarginine deiminases (2024-01-23),

9. 11806335 - Heterocyclic carboxylate compounds as glycolate oxidase inhibitors (2023-11-07),

10. 11793827 - Adenosine derivative and pharmaceutical composition comprising the same (2023-10-24),

11. 11352329 - HIV protease inhibitors (2022-06-07),

12. 11179397 - Imidazopyrimidine derivatives (2021-11-23),

13. 10800772 - Therapeutic compounds (2020-10-13),

14. 10774053 - HIV protease inhibitors (2020-09-15),

15. 9981955 - Antiviral compounds (2018-05-29),

Title: Lianhong Xu: Pioneering Inventor in Technological Advancements

Introduction:

Lianhong Xu, a visionary inventor based in Palo Alto, CA, is renowned for his relentless passion for innovation and remarkable technical expertise. With an impressive portfolio of 39 patents, Xu has made significant strides in the ever-evolving tech landscape, solidifying his reputation as a pioneer in the field.

Latest Patents:

Xu's latest patents showcase his ingenuity and commitment to advancing therapeutic treatments. The first patent pertains to "Inhibitors of peptidylarginine deiminases," focusing on novel compounds for treating diseases associated with PADs. The second patent highlights "Heterocyclic carboxylate compounds as glycolate oxidase inhibitors," demonstrating his profound impact on modulating the human glycolate oxidase enzyme for therapeutic purposes.

Career Highlights:

Throughout his esteemed career, Xu has contributed his expertise to renowned companies such as Gilead Sciences, Inc., and Gilead Pharmasset LLC. His innovative approach to problem-solving and dedication to pushing the boundaries of technology have set him apart as a trailblazer in his field.

Collaborations:

Xu's collaborative spirit is evident in his work with esteemed colleagues such as Hongtao Liu and Michael L. Mitchell. Together, they have strengthened the foundation of innovation within the technological realm, working towards groundbreaking solutions that have the potential to transform industries.

Conclusion:

In conclusion, Lianhong Xu's unwavering dedication to innovation, coupled with his technical acumen, has positioned him as a visionary inventor shaping the future of technology. His remarkable contributions to the field underscore his commitment to driving progress and revolutionizing the tech landscape for generations to come.

This text is generated by artificial intelligence and may not be accurate.